An observational analysis finds the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Media maven Oprah Winfrey stirred controversy during a recent “The Oprah Podcast” episode with Yale University obesity ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...